bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma
Authors: Siliņa Karīna , Soltermann Alex , Attar Farkhondeh Movahedian , Casanova Ruben , Uckeley Zina M. , Thut Helen , Wandres Muriel , Isajevs Sergejs , Cheng Phil , Curioni-Fontecedro Alessandra , Foukas Periklis , Levesque Mitchell P. , Moch Holger , Linē Aija , van den Broek Maries
Published: April 2023

Abstract
In solid tumors, the presence of lymph node–like structures called tertiary lymphoid structures (TLS) is associated with improved patient survival. However, little is known about how TLS develop in cancer, how their function affects survival, and whether they are affected by cancer therapy. In this study, we used multispectral microscopy, quantitative pathology, and gene expression profiling to analyze TLS formation in human lung squamous cell carcinoma (LSCC) and in an experimental model of lung TLS induction. We identified a niche of CXCL13+ perivascular and CXCL12+LTB+ and PD-L1+ epithelial cells supporting TLS formation. We also characterized sequential stages of TLS maturation in LSCC culminating in the formation of germinal centers (GC). In untreated patients, TLS density was the strongest independent prognostic marker. Furthermore, TLS density correlated with GC formation and expression of adaptive immune response–related genes. In patients treated with neoadjuvant chemotherapy, TLS density was similar, but GC formation was impaired and the prognostic value of TLS density was lost. Corticosteroids are coadministered with chemotherapy to manage side effects in LSCC patients, so we evaluated whether they impaired TLS development independently of chemotherapy. TLS density and GC formation were each reduced in chemotherapy-naïve LSCC patients treated with corticosteroids before surgery, compared with untreated patients, a finding that we confirmed in the experimental model of lung TLS induction. Overall, our results highlight the importance of GC formation in TLS during tumor development and treatment.

Significance: Corticosteroid treatment during chemotherapy negatively affects the development of tertiary lymphoid structures and abrogates their prognostic value in patients with lung cancer. Cancer Res; 78(5); 1308–20. ©2018 AACR.
Data from A Preclinical Model of Chronic Alcohol Consumption Reveals Increased Metastatic Seeding of Colon Cancer Cells in the Liver
Authors: Im Hwi-Jin , Kim Hyeong-Geug , Lee Jin-Seok , Kim Hyo-Seon , Cho Jung-Hyo , Jo Il-Joo , Park Sung-Joo , Son Chang-Gue
Published: April 2023

Abstract
Liver metastasis is the main cause of death from colorectal cancer. Alcohol consumption impacts liver function and is suggested to be an independent risk factor for liver metastasis of colorectal cancer, but no experimental evidence supporting this hypothesis has been demonstrated to date. In this study, we investigated the effect of alcohol intake on liver metastasis. We examined colon cancer cell spread from the spleen in mice provided with water (control group), alcohol for 4 weeks before tumor injection (prealcohol), alcohol for 3 weeks after tumor injection (postalcohol), or alcohol throughout the 7-week study (alcohol). Alcohol intake significantly increased hepatic metastatic burden in the prealcohol (2.4-fold, P < 0.001), postalcohol (2.0-fold, P < 0.01), and alcohol groups (2.2-fold, P < 0.001). A fluorescence-based metastasis tracking assay also confirmed an alcohol-induced increase in the abundance of tumor cells in the liver (2.5-fold, P < 0.001). Investigation of the host microenvironment revealed an alcohol-induced inflammatory response marked by elevated TNFα, IL1β, IL6, and IFNγ protein levels, as well as increased expression of intercellular molecule-1 (ICAM1) in hepatic tissues after 4 weeks of alcohol consumption. Moreover, the peripheral blood of mice provided with alcohol for 4 weeks exhibited reduced natural killer and CD8+ T-cell counts. Collectively, our findings suggest that chronic alcohol consumption accelerates liver metastasis of colorectal cancer cells through alterations to the liver microenvironment and inactivation of immune surveillance. Cancer Res; 76(7); 1698–704. ©2016 AACR.
Data from Myc Expression Drives Aberrant Lipid Metabolism in Lung Cancer
Authors: Hall Zoe , Ament Zsuzsanna , Wilson Catherine H. , Burkhart Deborah L. , Ashmore Tom , Koulman Albert , Littlewood Trevor , Evan Gerard I. , Griffin Julian L.
Published: April 2023

Abstract
MYC-mediated pathogenesis in lung cancer continues to attract interest for new therapeutic strategies. In this study, we describe a transgenic mouse model of KRAS-driven lung adenocarcinoma that affords reversible activation of MYC, used here as a tool for lipidomic profiling of MYC-dependent lung tumors formed in this model. Advanced mass spectrometric imaging and surface analysis techniques were used to characterize the spatial and temporal changes in lipid composition in lung tissue. We found that normal lung tissue was characterized predominantly by saturated phosphatidylcholines and phosphatidylglycerols, which are major lipid components of pulmonary surfactant. In contrast, tumor tissues displayed an increase in phosphatidylinositols and arachidonate-containing phospholipids that can serve as signaling precursors. Deactivating MYC resulted in a rapid and dramatic decrease in arachidonic acid and its eicosanoid metabolites. In tumors with high levels of MYC, we found an increase in cytosolic phospholipase A2 (cPLA2) activity with a preferential release of membrane-bound arachidonic acid, stimulating the lipoxygenase (LOX) and COX pathways also amplified by MYC at the level of gene expression. Deactivating MYC lowered cPLA2 activity along with COX2 and 5-LOX mRNA levels. Notably, inhibiting the COX/5-LOX pathways in vivo reduced tumor burden in a manner associated with reduced cell proliferation. Taken together, our results show how MYC drives the production of specific eicosanoids critical for lung cancer cell survival and proliferation, with possible implications for the use of COX and LOX pathway inhibitors for lung cancer therapy. Cancer Res; 76(16); 4608–18. ©2016 AACR.
Data from RASSF1A Directly Antagonizes RhoA Activity through the Assembly of a Smurf1-Mediated Destruction Complex to Suppress Tumorigenesis
Authors: Lee Min-Goo , Jeong Seong-In , Ko Kyung-Phil , Park Soon-Ki , Ryu Byung-Kyu , Kim Ick-Young , Kim Jeong-Kook , Chi Sung-Gil
Published: April 2023

Abstract
RASSF1A is a tumor suppressor implicated in many tumorigenic processes; however, the basis for its tumor suppressor functions are not fully understood. Here we show that RASSF1A is a novel antagonist of protumorigenic RhoA activity. Direct interaction between the C-terminal amino acids (256–277) of RASSF1A and active GTP-RhoA was critical for this antagonism. In addition, interaction between the N-terminal amino acids (69-82) of RASSF1A and the ubiquitin E3 ligase Smad ubiquitination regulatory factor 1 (Smurf1) disrupted GTPase activity by facilitating Smurf1-mediated ubiquitination of GTP-RhoA. We noted that the RhoA-binding domain of RASSF1A displayed high sequence homology with Rho-binding motifs in other RhoA effectors, such as Rhotekin. As predicted on this basis, RASSF1A competed with Rhotekin to bind RhoA and to block its activation. RASSF1A mutants unable to bind RhoA or Smurf1 failed to suppress RhoA-induced tumor cell proliferation, drug resistance, epithelial–mesenchymal transition, migration, invasion, and metastasis. Clinically, expression levels of RASSF1A and RhoA were inversely correlated in many types of primary and metastatic tumors and tumor cell lines. Collectively, our findings showed how RASSF1A may suppress tumorigenesis by intrinsically inhibiting the tumor-promoting activity of RhoA, thereby illuminating the potential mechanistic consequences of RASSF1A inactivation in many cancers. Cancer Res; 76(7); 1847–59. ©2016 AACR.
Data from Notch4 Signaling Induces a Mesenchymal–Epithelial–like Transition in Melanoma Cells to Suppress Malignant Behaviors
Authors: Bonyadi Rad Ehsan , Hammerlindl Heinz , Wels Christian , Popper Ulrich , Ravindran Menon Dinoop , Breiteneder Heimo , Kitzwoegerer Melitta , Hafner Christine , Herlyn Meenhard , Bergler Helmut , Schaider Helmut
Published: April 2023

Abstract
The effects of Notch signaling are context-dependent and both oncogenic and tumor-suppressive functions have been described. Notch signaling in melanoma is considered oncogenic, but clinical trials testing Notch inhibition in this malignancy have not proved successful. Here, we report that expression of the constitutively active intracellular domain of Notch4 (N4ICD) in melanoma cells triggered a switch from a mesenchymal-like parental phenotype to an epithelial-like phenotype. The epithelial-like morphology was accompanied by strongly reduced invasive, migratory, and proliferative properties concomitant with the downregulation of epithelial–mesenchymal transition markers Snail2 (SNAI2), Twist1, vimentin (VIM), and MMP2 and the reexpression of E-cadherin (CDH1). The N4ICD-induced phenotypic switch also resulted in significantly reduced tumor growth in vivo. Immunohistochemical analysis of primary human melanomas and cutaneous metastases revealed a significant correlation between Notch4 and E-cadherin expression. Mechanistically, we demonstrate that N4ICD induced the expression of the transcription factors Hey1 and Hey2, which bound directly to the promoter regions of Snail2 and Twist1 and repressed gene transcription, as determined by EMSA and luciferase assays. Taken together, our findings indicate a role for Notch4 as a tumor suppressor in melanoma, uncovering a potential explanation for the poor clinical efficacy of Notch inhibitors observed in this setting. Cancer Res; 76(7); 1690–7. ©2016 AACR.
Data from A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy
Authors: Makvandi Mehran , Xu Kuiying , Lieberman Brian P. , Anderson Redmond-Craig , Effron Samuel Sander , Winters Harrison D. , Zeng Chenbo , McDonald Elizabeth S. , Pryma Daniel A. , Greenberg Roger A. , Mach Robert H.
Published: April 2023

Abstract
Despite the availability of PARP inhibitors for cancer therapy, a biomarker to clearly stratify patients for selection of this treatment remains lacking. Here we describe a radiotracer-based method that addresses this issue, using the novel compound [125I]KX1 as a PARP-1–selective radiotracer that can accurately measure PARP-1 expression in vitro and in vivo. The pharmacologic properties of the PARP radiotracer [125I]KX1 was characterized in multiple cell lines where single-agent sensitivity was correlated with [125I]KX1 binding to PARP-1. In vivo evaluation of [125I]KX1 verified in vitro results, validating PARP radiotracers to define PARP-1 enzyme expression as an in vivo biomarker. Notably, PARP-1 expression as quantified by [125I]KX1 correlated positively with the cytotoxic sensitivity of cell lines evaluated with PARP inhibitors. Overall, our results defined a novel technology with the potential to serve as a companion diagnostic to identify patients most likely to respond therapeutically to a PARP inhibitor. Cancer Res; 76(15); 4516–24. ©2016 AACR.
Data from Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells
Authors: Tang Chih-Hang Anthony , Zundell Joseph A. , Ranatunga Sujeewa , Lin Cindy , Nefedova Yulia , Del Valle Juan R. , Hu Chih-Chi Andrew
Published: April 2023

Abstract
Endoplasmic reticulum (ER) stress responses through the IRE-1/XBP-1 pathway are required for the function of STING (TMEM173), an ER-resident transmembrane protein critical for cytoplasmic DNA sensing, IFN production, and cancer control. Here we show that the IRE-1/XBP-1 pathway functions downstream of STING and that STING agonists selectively trigger mitochondria-mediated apoptosis in normal and malignant B cells. Upon stimulation, STING was degraded less efficiently in B cells, implying that prolonged activation of STING can lead to apoptosis. Transient activation of the IRE-1/XBP-1 pathway partially protected agonist-stimulated malignant B cells from undergoing apoptosis. In Eμ-TCL1 mice with chronic lymphocytic leukemia, injection of the STING agonist 3′3′-cGAMP induced apoptosis and tumor regression. Similarly efficacious effects were elicited by 3′3′-cGAMP injection in syngeneic or immunodeficient mice grafted with multiple myeloma. Thus, in addition to their established ability to boost antitumoral immune responses, STING agonists can also directly eradicate malignant B cells. Cancer Res; 76(8); 2137–52. ©2016 AACR.
Data from MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia
Authors: Sanjiv Kumar , Calderón-Montaño José Manuel , Pham Therese M. , Erkers Tom , Tsuber Viktoriia , Almlöf Ingrid , Höglund Andreas , Heshmati Yaser , Seashore-Ludlow Brinton , Nagesh Danda Akhilesh , Gad Helge , Wiita Elisee , Göktürk Camilla , Rasti Azita , Friedrich Stefanie , Centio Anders , Estruch Montserrat , Våtsveen Thea Kristin , Struyf Nona , Visnes Torkild , Scobie Martin , Koolmeister Tobias , Henriksson Martin , Wallner Olov , Sandvall Teresa , Lehmann Sören , Theilgaard-Mönch Kim , Garnett Mathew J. , Östling Päivi , Walfridsson Julian , Helleday Thomas , Warpman Berglund Ulrika
Published: April 2023

Abstract
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, exhibiting high levels of reactive oxygen species (ROS). ROS levels have been suggested to drive leukemogenesis and is thus a potential novel target for treating AML. MTH1 prevents incorporation of oxidized nucleotides into the DNA to maintain genome integrity and is upregulated in many cancers. Here we demonstrate that hematologic cancers are highly sensitive to MTH1 inhibitor TH1579 (karonudib). A functional precision medicine ex vivo screen in primary AML bone marrow samples demonstrated a broad response profile of TH1579, independent of the genomic alteration of AML, resembling the response profile of the standard-of-care treatments cytarabine and doxorubicin. Furthermore, TH1579 killed primary human AML blast cells (CD45+) as well as chemotherapy resistance leukemic stem cells (CD45+Lin−CD34+CD38−), which are often responsible for AML progression. TH1579 killed AML cells by causing mitotic arrest, elevating intracellular ROS levels, and enhancing oxidative DNA damage. TH1579 showed a significant therapeutic window, was well tolerated in animals, and could be combined with standard-of-care treatments to further improve efficacy. TH1579 significantly improved survival in two different AML disease models in vivo. In conclusion, the preclinical data presented here support that TH1579 is a promising novel anticancer agent for AML, providing a rationale to investigate the clinical usefulness of TH1579 in AML in an ongoing clinical phase I trial.
Significance:
The MTH1 inhibitor TH1579 is a potential novel AML treatment, targeting both blasts and the pivotal leukemic stem cells while sparing normal bone marrow cells.
Supplementary Tables 1-6 from Intermediate- and Low-Methylation Epigenotypes Do Not Correspond to CpG Island Methylator Phenotype (Low and -Zero) in Colorectal Cancer
Authors: Karpinski Pawel , Walter Michael , Szmida Elzbieta , Ramsey David , Misiak Blazej , Kozlowska Joanna , Bebenek Marek , Grzebieniak Zygmunt , Blin Nikolaus , Laczmanski Lukasz , Sasiadek Maria M.
Published: April 2023

XLS file- 83KB, Methylation of CIMP-related markers and CRC cell lines epigenotyping. This file contains the data for Yagi's, Weisenberger's and Ogino's markers status in our HME, IME and LME pools and data acquired during CRC cell lines epigenotyping.
Supplemental Figure 4 from Medical Care Cost of Oropharyngeal Cancer among Texas Patients
Authors: Lairson David R. , Wu Chi-Fang , Chan Wenyaw , Dahlstrom Kristina R. , Tam Samantha , Sturgis Erich M.
Published: April 2023

The adjusted 1-year cost distributions between cases and controls
Supplementary Tables S1-S2 from Heme Iron Intake, Dietary Antioxidant Capacity, and Risk of Colorectal Adenomas in a Large Cohort Study of French Women
Authors: Bastide Nadia , Morois Sophie , Cadeau Claire , Kangas Suvi , Serafini Mauro , Gusto Gaëlle , Dossus Laure , Pierre Fabrice H. , Clavel-Chapelon Françoise , Boutron-Ruault Marie-Christine
Published: April 2023

Supplemental Table S1: Multivariable hazard ratio (HR, 95%CI) of proximal and distal colon adenomas and rectal adenomas by quartiles of heme iron intake according to dietary antioxidant intake. Supplemental Table S2: Multivariable hazard ratio (HR, 95%CI) of proximal and distal colon adenomas and rectal adenomas by quartiles of heme iron intake according to TRAP intake
Supplementary Table 1 from N-acetyltransferase 2 Phenotype, Occupation, and Bladder Cancer Risk: Results from the EPIC Cohort
Authors: Pesch Beate , Gawrych Katarzyna , Rabstein Sylvia , Weiss Tobias , Casjens Swaantje , Rihs Hans-Peter , Ding Hui , Angerer Jürgen , Illig Thomas , Klopp Norman , Bueno-de-Mesquita Bas , Ros Martine M. , Kaaks Rudolf , Chang-Claude Jenny , Roswall Nina , Tjønneland Anne , Overvad Kim , Clavel-Chapelon Françoise , Boutron-Ruault Marie-Christine , Dossus Laure , Boeing Heiner , Weikert Steffen , Trichopoulos Dimitrios , Palli Domenico , Sieri Sabina , Tumino Rosario , Panico Salvatore , Quirós José Ramón , González Carlos , Sánchez Mariá José , Dorronsoro Miren , Navarro Carmen , Barricarte Aurelio , Ljungberg Börje , Johansson Mattias , Ulmert David , Ehrnström Roy , Khaw Kay-Tee , Wareham Nick , Key Timothy J. , Ferrari Pietro , Romieu Isabelle , Riboli Elio , Brüning Thomas , Vineis Paolo
Published: April 2023

PDF - 84KB, Association of working in at-risk occupations with bladder cancer in men (609 cases and 665 controls) and women (145 cases and 168 controls) from EPIC.
Supplementary Figure 5 from Adult Stature and Risk of Cancer at Different Anatomic Sites in a Cohort of Postmenopausal Women
Authors: Kabat Geoffrey C. , Anderson Matthew L. , Heo Moonseong , Hosgood H. Dean , Kamensky Victor , Bea Jennifer W. , Hou Lifang , Lane Dorothy S. , Wactawski-Wende Jean , Manson JoAnn E. , Rohan Thomas E.
Published: April 2023

PDF - 68KB, Association of height with risk of endometrial cancer by level of potential effect modifiers. HR4s are adjusted for covariates in footnote 4 in Table 3.
Supplementary Figure 2 from Adult Stature and Risk of Cancer at Different Anatomic Sites in a Cohort of Postmenopausal Women
Authors: Kabat Geoffrey C. , Anderson Matthew L. , Heo Moonseong , Hosgood H. Dean , Kamensky Victor , Bea Jennifer W. , Hou Lifang , Lane Dorothy S. , Wactawski-Wende Jean , Manson JoAnn E. , Rohan Thomas E.
Published: April 2023

PDF - 68KB, Association of height with risk of colorectal cancer by level of potential effect modifiers. HR4s are adjusted for covariates in footnote 1 in Table 3.
Supplementary Figure 1 from Adult Stature and Risk of Cancer at Different Anatomic Sites in a Cohort of Postmenopausal Women
Authors: Kabat Geoffrey C. , Anderson Matthew L. , Heo Moonseong , Hosgood H. Dean , Kamensky Victor , Bea Jennifer W. , Hou Lifang , Lane Dorothy S. , Wactawski-Wende Jean , Manson JoAnn E. , Rohan Thomas E.
Published: April 2023

PDF - 68KB, Association of height with risk of breast cancer by level of potential effect modifiers. HR4s are adjusted for covariates in footnote 3 in Table 3.
Supplementary Table 1 from Risk Factors for Early Childhood Infection of Human Herpesvirus-8 in Zambian Children: The Role of Early Childhood Feeding Practices
Authors: Crabtree Kay L. , Wojcicki Janet M. , Minhas Veenu , Smith David R. , Kankasa Chipepo , Mitchell Charles D. , Wood Charles
Published: April 2023

PDF - 82KB, Univariable Analysis to Investigate the Association of Household and Personal Care Factors with Child HHV-8 Seropositivity in Lusaka, Zambia, 2004-2007.
Supplementary Figure 7 from Sex Disparities in Cancer Mortality and Survival
Authors: Cook Michael B. , McGlynn Katherine A. , Devesa Susan S. , Freedman Neal D. , Anderson William F.
Published: April 2023

PDF file - 101K
Supplementary Tables 1-4 from Associations between Testosterone Levels and Incident Prostate, Lung, and Colorectal Cancer. A Population-Based Study
Authors: Hyde Zoë , Flicker Leon , McCaul Kieran A. , Almeida Osvaldo P. , Hankey Graeme J. , Chubb S.A. Paul , Yeap Bu B.
Published: April 2023

PDF file - 94K, Competing-risks proportional hazards models exploring associations between hormonal parameters (categorised at the quintiles) and incident prostate cancer
Supplementary Figures 1 through 4 from Childhood Height and Birth Weight in Relation to Future Prostate Cancer Risk: A Cohort Study Based on the Copenhagen School Health Records Register
Authors: Cook Michael B. , Gamborg Michael , Aarestrup Julie , Sørensen Thorkild I.A. , Baker Jennifer L.
Published: April 2023

PDF - 73KB, Supplementary Figure 1. Flow chart of eligible and included subjects for analyses that included birth weight. Supplementary Figure 2. Distribution of cases by age at diagnosis Supplementary Figure 3. Incidence rate of prostate cancer by age of diagnosis Supplementary Figure 4. Illustration of the restricted cubic spline model at: (A) 7 years; (B) 13 years
Table S1 from Shifts in the Fecal Microbiota Associated with Adenomatous Polyps
Authors: Hale Vanessa L. , Chen Jun , Johnson Stephen , Harrington Sean C. , Yab Tracy C. , Smyrk Thomas C. , Nelson Heidi , Boardman Lisa A. , Druliner Brooke R. , Levin Theodore R. , Rex Douglas K. , Ahnen Dennis J. , Lance Peter , Ahlquist David A. , Chia Nicholas
Published: April 2023

Supplementary Table 1. MiRKAT association P values for various adenoma characteristics in individuals with adenomas
Supplementary Figure 31 from Sex Disparities in Cancer Mortality and Survival
Authors: Cook Michael B. , McGlynn Katherine A. , Devesa Susan S. , Freedman Neal D. , Anderson William F.
Published: April 2023

PDF file - 99K
Figure S2 from Shifts in the Fecal Microbiota Associated with Adenomatous Polyps
Authors: Hale Vanessa L. , Chen Jun , Johnson Stephen , Harrington Sean C. , Yab Tracy C. , Smyrk Thomas C. , Nelson Heidi , Boardman Lisa A. , Druliner Brooke R. , Levin Theodore R. , Rex Douglas K. , Ahnen Dennis J. , Lance Peter , Ahlquist David A. , Chia Nicholas
Published: April 2023

Supplementary Figure 2. Heat map of significantly predictive taxa. Hierarchical clustering is based on the Euclidean distance of log proportion, complete linkage. The left cluster is enriched in adenoma samples (P=0.1, Fisher's exact test).
Supplementary Figure 29 from Sex Disparities in Cancer Mortality and Survival
Authors: Cook Michael B. , McGlynn Katherine A. , Devesa Susan S. , Freedman Neal D. , Anderson William F.
Published: April 2023

PDF file - 97K
Supplementary Table 2 from Risk of Colorectal Cancer in Patients with Acute Myocardial Infarction and Stroke: A Nationwide Cohort Study
Authors: Erichsen Rune , Sværke Claus , Sørensen Henrik T. , Sandler Robert S. , Baron John A.
Published: April 2023

PDF - 64KB, Supplementary table showing results for stroke subtypes.
Supplementary Table 3 from Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer
Authors: Fahrmann Johannes F. , Kim Kyoungmi , DeFelice Brian C. , Taylor Sandra L. , Gandara David R. , Yoneda Ken Y. , Cooke David T. , Fiehn Oliver , Kelly Karen , Miyamoto Suzanne
Published: April 2023

Excel - 12 MB, Supplemental Table S3. Pearson correlations between circulating metabolites in serum and plasma during ADC1 and ADC2 (Excel Spreadsheet, four tabs in the following order: ADC1 plasma, ADC1 serum, ADC2 plasma, and ADC2 serum).
Supplementary Figure 16 from Sex Disparities in Cancer Mortality and Survival
Authors: Cook Michael B. , McGlynn Katherine A. , Devesa Susan S. , Freedman Neal D. , Anderson William F.
Published: April 2023

PDF file - 95K
Supplementary Materials and Methods. Supplementary Tables 1, 2, 4-6. Supplementary Figures 1-2 from Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer
Authors: Fahrmann Johannes F. , Kim Kyoungmi , DeFelice Brian C. , Taylor Sandra L. , Gandara David R. , Yoneda Ken Y. , Cooke David T. , Fiehn Oliver , Kelly Karen , Miyamoto Suzanne
Published: April 2023

Word - 708 KB, Supplementary Materials and Methods. Supplemental Table S1. All detected serum metabolites in ADC1 Training and ADC2 Test set. Supplemental Table S2. All detected plasma metabolites in ADC1 Training and ADC2 Test set. Supplemental Table S4. Serum metabolites significantly different (raw p-value <0.05) in both the ADC1 training and ADC2 test sets. Supplemental Table S5. Receiver Operating Characteristic Area Under the Curve (AUC) plus confidence intervals for top performing individual- and multi-metabolite classifiers based on overall accuracy for serum and plasma. Supplemental Table S6. Plasma metabolite significantly different (raw p-value < 0.05) in both the ADC1 training and ADC2 test sets. Supplemental Figure S2. Spectra of Unknown Bin_225393. Mass Spectrum for Unknown Bin_225393 (Retention Index 878347) is shown. Supplemental Figure S1. Plots for metabolites included in the serum- and plasma-classifiers in both the ADC1 (training) and ADC2 (test) sets.
Supplementary Figure 15 from Sex Disparities in Cancer Mortality and Survival
Authors: Cook Michael B. , McGlynn Katherine A. , Devesa Susan S. , Freedman Neal D. , Anderson William F.
Published: April 2023

PDF file - 103K
Supplementary Figure 13 from Sex Disparities in Cancer Mortality and Survival
Authors: Cook Michael B. , McGlynn Katherine A. , Devesa Susan S. , Freedman Neal D. , Anderson William F.
Published: April 2023

PDF file - 101K
Supplementary Table 1 from Menthol Cigarettes, Race/Ethnicity, and Biomarkers of Tobacco Use in U.S. Adults: The 1999–2010 National Health and Nutrition Examination Survey (NHANES)
Authors: Jones Miranda R. , Apelberg Benjamin J. , Tellez-Plaza Maria , Samet Jonathan M. , Navas-Acien Ana
Published: April 2023

PDF file - 67K, Participant Characteristics by Race/Ethnicity
Supplementary Figure 12 from Sex Disparities in Cancer Mortality and Survival
Authors: Cook Michael B. , McGlynn Katherine A. , Devesa Susan S. , Freedman Neal D. , Anderson William F.
Published: April 2023

PDF file - 102K
Supplementary Table 1 from Racial Differences in the Incidence and Clearance of Human Papilloma Virus (HPV): The HPV in Men (HIM) Study
Authors: Schabath Matthew B. , Villa Luisa L. , Lin Hui-Yi , Fulp William J. , Akogbe Gabriel O. , Abrahamsen Martha E. , Papenfuss Mary R. , Lazcano-Ponce Eduardo , Salmerón Jorge , Quiterio Manuel , Giuliano Anna R.
Published: April 2023

PDF - 65K, Hazard ratios for incidence and clearance of HPV infection by race and stratified by number of lifetime female partners.
Table S4 from Inherited Genetic Variants Associated with Occurrence of Multiple Primary Melanoma
Authors: Gibbs David C. , Orlow Irene , Kanetsky Peter A. , Luo Li , Kricker Anne , Armstrong Bruce K. , Anton-Culver Hoda , Gruber Stephen B. , Marrett Loraine D. , Gallagher Richard P. , Zanetti Roberto , Rosso Stefano , Dwyer Terence , Sharma Ajay , La Pilla Emily , From Lynn , Busam Klaus J. , Cust Anne E. , Ollila David W. , Begg Colin B. , Berwick Marianne , Thomas Nancy E.
Published: April 2023

Table S4. Genotype and haplotype associations with phenotypic index and back nevi in the GEM study
Supplementary Appendix 2 from A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of BRCA1 and BRCA2 Mutation Carriers
Authors: Sigal Bronislava M. , Munoz Diego F. , Kurian Allison W. , Plevritis Sylvia K.
Published: April 2023

PDF file, 120KB, Natural History Model of Breast Cancer in BRCA1/2 Mutation Carriers.
Table S3 from Inherited Genetic Variants Associated with Occurrence of Multiple Primary Melanoma
Authors: Gibbs David C. , Orlow Irene , Kanetsky Peter A. , Luo Li , Kricker Anne , Armstrong Bruce K. , Anton-Culver Hoda , Gruber Stephen B. , Marrett Loraine D. , Gallagher Richard P. , Zanetti Roberto , Rosso Stefano , Dwyer Terence , Sharma Ajay , La Pilla Emily , From Lynn , Busam Klaus J. , Cust Anne E. , Ollila David W. , Begg Colin B. , Berwick Marianne , Thomas Nancy E.
Published: April 2023

Table S3. Association of haplotypes with multiple primary melanoma in the GEM study
Table S1 from Inherited Genetic Variants Associated with Occurrence of Multiple Primary Melanoma
Authors: Gibbs David C. , Orlow Irene , Kanetsky Peter A. , Luo Li , Kricker Anne , Armstrong Bruce K. , Anton-Culver Hoda , Gruber Stephen B. , Marrett Loraine D. , Gallagher Richard P. , Zanetti Roberto , Rosso Stefano , Dwyer Terence , Sharma Ajay , La Pilla Emily , From Lynn , Busam Klaus J. , Cust Anne E. , Ollila David W. , Begg Colin B. , Berwick Marianne , Thomas Nancy E.
Published: April 2023

Table S1. Demographic and phenotypic characteristics among muliple and single primary melanoma patients in the GEM study
Supplementary Figure S3 from Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm
Authors: Sun Xiangqing , Elston Robert C. , Barnholtz-Sloan Jill S. , Falk Gary W. , Grady William M. , Faulx Ashley , Mittal Sumeet K. , Canto Marcia , Shaheen Nicholas J. , Wang Jean S. , Iyer Prasad G. , Abrams Julian A. , Tian Ye D. , Willis Joseph E. , Guda Kishore , Markowitz Sanford D. , Chandar Apoorva , Warfe James M. , Brock Wendy , Chak Amitabh
Published: April 2023

The joint linearity of the categorical covariates on the logit scale
Supplementary Table 1 from BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics
Authors: Phipps Amanda I. , Buchanan Daniel D. , Makar Karen W. , Burnett-Hartman Andrea N. , Coghill Anna E. , Passarelli Michael N. , Baron John A. , Ahnen Dennis J. , Win Aung Ko , Potter John D. , Newcomb Polly A.
Published: April 2023

PDF file, 73K, BRAF mutation status and survival after colorectal cancer diagnosis by patient and tumor characteristics, excluding cases with unknown MSI status.
Supplementary Figure S1 from Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm
Authors: Sun Xiangqing , Elston Robert C. , Barnholtz-Sloan Jill S. , Falk Gary W. , Grady William M. , Faulx Ashley , Mittal Sumeet K. , Canto Marcia , Shaheen Nicholas J. , Wang Jean S. , Iyer Prasad G. , Abrams Julian A. , Tian Ye D. , Willis Joseph E. , Guda Kishore , Markowitz Sanford D. , Chandar Apoorva , Warfe James M. , Brock Wendy , Chak Amitabh
Published: April 2023

The relationship of age and date of birth (DOB) in the data
Supplementary Figure 1 from Increased Levels of Tetra-antennary N-Linked Glycan but Not Core Fucosylation Are Associated with Hepatocellular Carcinoma Tissue
Authors: Mehta Anand , Norton Pamela , Liang Hongyan , Comunale Mary Ann , Wang Mengjun , Rodemich-Betesh Lucy , Koszycki Alex , Noda Katsuhisa , Miyoshi Eiji , Block Timothy
Published: April 2023

PDF file, 354KB, N-linked glycosylation of total protein from 16 HCC tissue and adjacent liver tissue pairs.
Supplementary Table S1 from Aspirin Use and Risk of Breast Cancer: Systematic Review and Meta-analysis of Observational Studies
Authors: Zhong Shanliang , Chen Lin , Zhang Xiaohui , Yu Dandan , Tang Jinhai , Zhao Jianhua
Published: April 2023

Methodological quality of the cohort studies, based on the NOS for assessing the quality of epidemiological studies.
Supplementary Figure Legend from Aspirin Use and Risk of Breast Cancer: Systematic Review and Meta-analysis of Observational Studies
Authors: Zhong Shanliang , Chen Lin , Zhang Xiaohui , Yu Dandan , Tang Jinhai , Zhao Jianhua
Published: April 2023

Supplementary Figure Legend
Supplemental Tables S1-S3 and Figure S1 from Postdiagnosis Weight Change and Survival Following a Diagnosis of Early-Stage Breast Cancer
Authors: Cespedes Feliciano Elizabeth M. , Kroenke Candyce H. , Bradshaw Patrick T. , Chen Wendy Y. , Prado Carla M. , Weltzien Erin K. , Castillo Adrienne L. , Caan Bette J.
Published: April 2023

Supplemental Figure S1. Post-Diagnosis Weight Change and Breast Cancer-Specific Mortality. Supplemental Table S1. Category of Weight Change and All-cause Mortality by Follow-Up Period. Supplemental Table S2. Average Association of Post-Diagnosis Weight Change and All-cause and Breast Cancer-Specific Mortality by Subgroup. Supplemental Table S3. Average Association of Post-Diagnosis Weight Change and Breast Cancer-Specific and All-cause Mortality by Immunohistochemistry.
Supplementary Figure Legend from Germline Missense Variants in the BTNL2 Gene Are Associated with Prostate Cancer Susceptibility
Authors: FitzGerald Liesel M. , Kumar Akash , Boyle Evan A. , Zhang Yuzheng , McIntosh Laura M. , Kolb Suzanne , Stott-Miller Marni , Smith Tiffany , Karyadi Danielle M. , Ostrander Elaine A. , Hsu Li , Shendure Jay , Stanford Janet L.
Published: April 2023

PDF - 59K, Legend for Supplementary Figure 1.
Supplementary Table 1 from Multistage Analysis of Variants in the Inflammation Pathway and Lung Cancer Risk in Smokers
Authors: Spitz Margaret R. , Gorlov Ivan P. , Dong Qiong , Wu Xifeng , Chen Wei , Chang David W. , Etzel Carol J. , Caporaso Neil E. , Zhao Yang , Christiani David C. , Brennan Paul , Albanes Demetrius , Shi Jianxin , Thun Michael , Landi Maria Teresa , Amos Christopher I.
Published: April 2023

PDF file - 54K, Summary of Inflammation subpathways, genes and SNP's in Illumina chip
Supplementary Tables S3-S13 from Solid Tumors of Childhood Display Specific Serum microRNA Profiles
Authors: Murray Matthew J. , Raby Katie L. , Saini Harpreet K. , Bailey Shivani , Wool Sophie V. , Tunnacliffe Jane M. , Enright Anton J. , Nicholson James C. , Coleman Nicholas
Published: April 2023

Supplementary Tables S3 to S13. Over-expressed serum microRNAs in individual types of solid tumor of childhood. The Tables list the over-expressed microRNAs in individual types of solid tumor of childhood compared with the 'other tumor' group and control group, their fold-changes, coefficient of variation and robust rank aggregate (RRA) score. Key: FC =fold-change; CV = coefficient of variation. Table S3: MYCN-amplified INRG high-risk neuroblastoma (MYCN-NB). Table S4: non-MYCN-amplified INRG low-risk neuroblastoma (NB). Table S5: mhepatoblastoma(HB). Table S6: Wilms tumor (WT). Table S7 = rhabdomyosarcoma (RMS). Table S8: Ewings sarcoma (ES). Table S9: osteosarcoma (OS). Table S10: B-cell non-Hodgkin's lymphoma (BNHL). Table S11: Hodgkin's disease (HD). Table S12: pleuropulmonary blastoma (PPB) Table S13: Central nervous system glioma (GL).
Supplementary Materials, Tables S1 and S2, Figures S1-S10 from Solid Tumors of Childhood Display Specific Serum microRNA Profiles
Authors: Murray Matthew J. , Raby Katie L. , Saini Harpreet K. , Bailey Shivani , Wool Sophie V. , Tunnacliffe Jane M. , Enright Anton J. , Nicholson James C. , Coleman Nicholas
Published: April 2023

Supplementary Materials, Tables S1 and S2, Figures S1-S10. Supplementary Table S1. Number of over-expressed serum microRNAs in solid tumor types of childhood. Supplementary Table S2. Ten over-expressed serum microRNAs selected for the technical confirmation qRT-PCR study. Supplementary Table and Figure Legends, Supplementary References. Supplementary Figure S1. Quality control (QC) assessments in the initial qRT-PCR run. Supplementary Figure S2. Confirmation of suitability of the four serum QC housekeeping microRNAs for screening samples for the full discovery-phase qRT-PCR run. Supplementary Figure S3. QC assessments in the full discovery-phase qRT-PCR run. Supplementary Figure S4. Hemolysis assessment of the 53 serum samples in the initial QC and full discovery-phase qRT-PCR run. Supplementary Figure S5. Further QC assessment of the 53 serum samples in the full discovery-phase qRT-PCR run. Supplementary Figure S6. Top-ranking overlapping housekeeping microRNAs identified by NormFinder and geNorm algorithms, suitable for targeted serum qRT-PCR studies. Supplementary Figure S7. Comparison of expression of miR-122-3p and miR-122-5p in the 53 serum samples in the full discovery-phase qRT-PCR run. Supplementary Figure S8. Comparison of the average raw Ct values in the 21 serum samples common to both the full discovery-phase and technical confirmation qRT-PCR run. Supplementary Figure S9. QC assessment in the technical confirmation qRT-PCR run for all 25 serum samples used. Supplementary Figure S10. Serum microRNA expression in osteosarcoma.
Supplementary Figure 1 from Benign Breast Tissue Composition in Breast Cancer Patients: Association with Risk Factors, Clinical Variables, and Gene Expression
Authors: Sun Xuezheng , Sandhu Rupninder , Figueroa Jonine D. , Gierach Gretchen L. , Sherman Mark E. , Troester Melissa A.
Published: April 2023

Supplementary Figure 1 - Principle component analysis showed considerable homogeneity of global gene expression in the test and training data sets.
Supplementary Table 4 from Germline Variants in DNA Repair Genes, Diagnostic Radiation, and Risk of Thyroid Cancer
Authors: Sandler Jason E. , Huang Huang , Zhao Nan , Wu Weiwei , Liu Fangfang , Ma Shuangge , Udelsman Robert , Zhang Yawei
Published: April 2023

Statistically significant effect modification of genotypes between diagnostic radiation exposure and risk of thyroid cancer with large tumor size (n=694).
Supplementary Table 3 from Germline Variants in DNA Repair Genes, Diagnostic Radiation, and Risk of Thyroid Cancer
Authors: Sandler Jason E. , Huang Huang , Zhao Nan , Wu Weiwei , Liu Fangfang , Ma Shuangge , Udelsman Robert , Zhang Yawei
Published: April 2023

Statistically significant effect modification of genotypes between diagnostic radiation exposure and risk of papillary thyroid microcarcinoma (n=645).
Supplementary Table 2 from Germline Variants in DNA Repair Genes, Diagnostic Radiation, and Risk of Thyroid Cancer
Authors: Sandler Jason E. , Huang Huang , Zhao Nan , Wu Weiwei , Liu Fangfang , Ma Shuangge , Udelsman Robert , Zhang Yawei
Published: April 2023

Association between diagnostic radiation exposure and risk of thyroid cancer (n=905).
Supplementary Table S1 from Inflammatory Markers of CRP, IL6, TNFα, and Soluble TNFR2 and the Risk of Ovarian Cancer: A Meta-analysis of Prospective Studies
Authors: Zeng Fangfang , Wei Huishan , Yeoh Engkiong , Zhang Zheqing , Ren Ze-Fang , Colditz Graham A. , Tworoger Shelley S. , Su Xuefen
Published: April 2023

Other characteristics and main results of studies included in the meta-analysis
Table S5. Methylation ratio at each CpG for all samples from Targeted, Deep Sequencing Reveals Full Methylation Profiles of Multiple HPV Types and Potential Biomarkers for Cervical Cancer Progression
Authors: Liu Pengyuan , Iden Marissa , Fye Samantha , Huang Yi-Wen , Hopp Elizabeth , Chu Chen , Lu Yan , Rader Janet S.
Published: April 2023

Each sample is listed with methylation ratios at each CpG in the corresponding HPV genome.
Table S1. Subject characteristics for pyrosequencing from Targeted, Deep Sequencing Reveals Full Methylation Profiles of Multiple HPV Types and Potential Biomarkers for Cervical Cancer Progression
Authors: Liu Pengyuan , Iden Marissa , Fye Samantha , Huang Yi-Wen , Hopp Elizabeth , Chu Chen , Lu Yan , Rader Janet S.
Published: April 2023

Relevant clinical information on subject used for pyrosequencing validation.
Supplementary Figure 8 from Biomarker Discovery for Heterogeneous Diseases
Authors: Wallstrom Garrick , Anderson Karen S. , LaBaer Joshua
Published: April 2023

PDF file - 3299K, Figure S8. Estimated power of the ordinary t-test and empirical Bayes moderated t-test with FDR controlled at 10% for single-stage design using 25, 50, 100, or 200 patients and controls with normal samples for a heterogeneous disease.
Supplementary Figure 7 from Biomarker Discovery for Heterogeneous Diseases
Authors: Wallstrom Garrick , Anderson Karen S. , LaBaer Joshua
Published: April 2023

PDF file - 3281K, Figure S7. Estimated power of the ordinary t-test and empirical Bayes moderated t-test with FDR controlled at 10% for single-stage design using 25, 50, 100, or 200 patients and controls with normal samples for a homogeneous disease.
Supplementary Figure 6 from Biomarker Discovery for Heterogeneous Diseases
Authors: Wallstrom Garrick , Anderson Karen S. , LaBaer Joshua
Published: April 2023

PDF file - 5388K, Figure S6. Estimated power with FDR controlled at 50% for a two-stage design using 200 total patients and 200 total controls with normal samples for a (a) homogeneous disease and a (b) heterogeneous disease.
Supplementary Figure 4 from Biomarker Discovery for Heterogeneous Diseases
Authors: Wallstrom Garrick , Anderson Karen S. , LaBaer Joshua
Published: April 2023

PDF file - 5375K, Figure S4. Estimated power with FDR controlled at 50% for single stage design using t3 samples for a (a) homogeneous disease and a (b) heterogeneous disease.
Supplementary Tables 1-8 from Common Genetic Variants in Prostate Cancer Risk Prediction—Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)
Authors: Lindström Sara , Schumacher Fredrick R. , Cox David , Travis Ruth C. , Albanes Demetrius , Allen Naomi E. , Andriole Gerald , Berndt Sonja I. , Boeing Heiner , Bueno-de-Mesquita H. Bas , Crawford E. David , Diver W. Ryan , Gaziano J. Michael , Giles Graham G. , Giovannucci Edward , Gonzalez Carlos A. , Henderson Brian , Hunter David J. , Johansson Mattias , Kolonel Laurence N. , Ma Jing , Le Marchand Loïc , Pala Valeria , Stampfer Meir , Stram Daniel O. , Thun Michael J. , Tjonneland Anne , Trichopoulos Dimitrios , Virtamo Jarmo , Weinstein Stephanie J. , Willett Walter C. , Yeager Meredith , Hayes Richard B. , Severi Gianluca , Haiman Christopher A. , Chanock Stephen J. , Kraft Peter
Published: April 2023

PDF file - 169K
Supplementary Figure 1 from High Mammographic Density in Long-Term Night-Shift Workers: DDM-Spain/Var-DDM
Authors: Pedraza-Flechas Ana María , Lope Virginia , Sánchez-Contador Carmen , Santamariña Carmen , Pedraz-Pingarrón Carmen , Moreo Pilar , Ederra María , Miranda-García Josefa , Vidal Carmen , Llobet Rafael , Aragonés Nuria , Salas-Trejo Dolores , Pollán Marina , Pérez-Gómez Beatriz
Published: April 2023

Supplementary Figure 1. Graphic esqueme summarizing the proposed pathways of the association between night-shift work and mammographic density.
Supplemental Table 2 from Opportunities and Challenges for the Use of Large-Scale Surveys in Public Health Research: A Comparison of the Assessment of Cancer Screening Behaviors
Authors: Hamilton Jada G. , Breen Nancy , Klabunde Carrie N. , Moser Richard P. , Leyva Bryan , Breslau Erica S. , Kobrin Sarah C.
Published: April 2023

Supplemental Table 2. Publications using cancer screening construct data collected through the National Health Interview Survey (NHIS), Health Information National Trends Survey (HINTS), Behavioral Risk Factor Surveillance Survey (BRFSS), and California Health Information Survey (CHIS), 2005
Supplementary Figure 1 from Work Loss Duration and Predictors Following Rectal Cancer Treatment among Patients with and without Prediagnostic Work Loss
Authors: Chen Lingjing , Glimelius Ingrid , Neovius Martin , Ekberg Sara , Martling Anna , Eloranta Sandra , Smedby Karin E.
Published: April 2023

Supplementary Figure S1. Annual distribution of patients by extent of annual work loss (0, 1-180, 181-359 and >360 days) from two years before to five years after rectal cancer diagnosis for relapse-free patients without pre-diagnostic work loss before diagnosis (n=2529) and with pre-diagnostic work loss (sick leave only n=500, or disability pension n=409).
Supplementary Table S1 from Expanding Epigenomics to Archived FFPE Tissues: An Evaluation of DNA Repair Methodologies
Authors: Siegel Erin M. , Berglund Anders E. , Riggs Bridget M. , Eschrich Steven A. , Putney Ryan M. , Ajidahun Abidemi O. , Coppola Domenico , Shibata David
Published: April 2023

Supplementary Table 1. Patient, tumor and sample characteristics of paired FF and FFPE colorectal tumors.
Data from Cancer Mortality Risks from Long-term Exposure to Ambient Fine Particle
Authors: Wong Chit Ming , Tsang Hilda , Lai Hak Kan , Thomas G. Neil , Lam Kin Bong , Chan King Pan , Zheng Qishi , Ayres Jon G. , Lee Siu Yin , Lam Tai Hing , Thach Thuan Quoc
Published: April 2023

Abstract
Background: Few studies have assessed long-term effects of particulate matter (PM) with aerodynamic diameter < 2.5 μm (PM2.5) on mortality for causes of cancer other than the lung; we assessed the effects on multiple causes. In Hong Kong, most people live and work in urban or suburban areas with high-rise buildings. This facilitates the estimation of PM2.5 exposure of individuals, taking into account the height of residence above ground level for assessment of the long-term health effects with sufficient statistical power.

Methods: We recruited 66,820 persons who were ≥65 in 1998 to 2001 and followed up for mortality outcomes until 2011. Annual concentrations of PM at their residential addresses were estimated using PM2.5 concentrations measured at fixed-site monitors, horizontal–vertical locations, and satellite data. We used Cox regression model to assess the HR of mortality for cancer per 10 μg/m3 increase of PM2.5.

Results: PM2.5 was associated with increased risk of mortality for all causes of cancer [HR, 1.22 (95% CI, 1.11–1.34)] and for specific cause of cancer in upper digestive tract [1.42 (1.06–1.89)], digestive accessory organs [1.35 (1.06–1.71)] in all subjects; breast [1.80 (1.26–2.55)] in females; and lung [1.36 (1.05–1.77)] in males.

Conclusions: Long-term exposures to PM2.5 are associated with elevated risks of cancer in various organs.

Impact: This study is particularly timely in China, where compelling evidence is needed to support the pollution control policy to ameliorate the health damages associated with economic growth. Cancer Epidemiol Biomarkers Prev; 25(5); 839–45. ©2016 AACR.
Data from Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes
Authors: Chavez-MacGregor Mariana , Liu Shuying , De Melo-Gagliato Debora , Chen Huiqin , Do Kim-Anh , Pusztai Lajos , Fraser Symmans W. , Nair Lakshmy , Hortobagyi Gabriel N. , Mills Gordon B. , Meric-Bernstam Funda , Gonzalez-Angulo Ana M.
Published: April 2023

Abstract
Background: Differences in gene or protein expression patterns between breast cancers according to race/ethnicity and cancer subtype.

Methods: Transcriptional profiling was performed using Affymetrix HG-U133A platform in 376 patients and reverse phase protein array analysis (RPPA) was done for 177 proteins in 255 patients from a separate cohort. Unsupervised clustering was conducted, as well as supervised comparison by race and tumor subtype. Standard statistical methods, BRB-Array tools, and Ingenuity Pathways software packages were used to analyze the data.

Results: Median age was 50 years in both the cohorts. In the RPPA cohort, 54.5% of the tumors were hormone receptor–positive (HR-positive), 20.7% HER2-positive, and 24.71% triple-negative (TNBC). One hundred and forty-seven (57.6%), 47 (18.43%), and 46 (18.1%) of the patients were White, Hispanic, and Black, respectively. Unsupervised hierarchical clustering of the protein expression data showed no distinct clusters by race (P values were 0.492, 0.489, and 0.494 for the HR-positive, HER2-positive, and TNBC tumors respectively). In the gene expression cohort, 54.2% of the tumors were HR-positive, 16.5% HER2-positive, and 29.3% TNBC. Two hundred and sixteen (57.5%), 111 (29.52%), and 32 (8.52%) patients were White, Hispanic, and Black, respectively. No probe set with a false discovery rate (FDR) of <0.05 showed an association with race by breast cancer subtype; similar results were obtained using pathway and gene set enrichment analysis methods.

Conclusions: We did not detect a significant variation in RNA or protein expression comparing different race/ethnicity groups of women with breast cancer.

Impact: More research on the complex network of factors that result in outcomes differences among race/ethnicities is needed. Cancer Epidemiol Biomarkers Prev; 23(2); 316–23. ©2013 AACR.